RNA interference-based therapy and its delivery systems

1.

Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391(6669), 806–811. https://doi.org/10.1038/35888.PubMedCrossRef

2.

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411(6836), 494–498. https://doi.org/10.1038/35078107.PubMedCrossRef

3.

Davis, M. E., Zuckerman, J. E., Choi, C. H., Seligson, D., Tolcher, A., Alabi, C. A., et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464(7291), 1067–1070. https://doi.org/10.1038/nature08956.PubMedPubMedCentralCrossRef

4.

Tatiparti, K., Sau, S., Kashaw, S. K., & Iyer, A. K. (2017). siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials (Basel), 7(4). https://doi.org/10.3390/nano7040077.

5.

Costa, F. F. (2007). Non-coding RNAs: lost in translation? Gene, 386(1–2), 1–10. https://doi.org/10.1016/j.gene.2006.09.028.PubMed

6.

Mansoori, B., Sandoghchian Shotorbani, S., & Baradaran, B. (2014). RNA interference and its role in cancer therapy. Advanced Pharmaceutical Bulletin, 4(4), 313–321. https://doi.org/10.5681/apb.2014.046.PubMedPubMedCentral

7.

Cao, J. (2014). The functional role of long non-coding RNAs and epigenetics. Biological Procedures Online, 16, 11. https://doi.org/10.1186/1480-9222-16-11.PubMedPubMedCentralCrossRef

8.

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.PubMedCrossRef

9.

Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009). siRNA vs. shRNA: similarities and differences. Advanced Drug Delivery Reviews, 61(9), 746–759. https://doi.org/10.1016/j.addr.2009.04.004.PubMedCrossRef

10.

Macfarlane, L. A., & Murphy, P. R. (2010). MicroRNA: biogenesis, function and role in cancer. Current Genomics, 11(7), 537–561. https://doi.org/10.2174/138920210793175895.PubMedPubMedCentralCrossRef

11.

Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., et al. (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369(9555), 29–36. https://doi.org/10.1016/S0140-6736(07)60028-2.PubMedCrossRef

12.

Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine, 355(23), 2408–2417. https://doi.org/10.1056/NEJMoa062867.PubMedCrossRef

13.

Weiss, W. A., Taylor, S. S., & Shokat, K. M. (2007). Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nature Chemical Biology, 3(12), 739–744. https://doi.org/10.1038/nchembio1207-739.PubMedPubMedCentralCrossRef

14.

Eggert, U. S., Field, C. M., & Mitchison, T. J. (2006). Small molecules in an RNAi world. Molecular BioSystems, 2(2), 93–96. https://doi.org/10.1039/b515335b.PubMedCrossRef

15.

Arkin, M. R., Tang, Y., & Wells, J. A. (2014). Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chemistry & Biology, 21(9), 1102–1114. https://doi.org/10.1016/j.chembiol.2014.09.001.CrossRef

16.

Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016). miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discovery, 6(3), 235–246. https://doi.org/10.1158/2159-8290.CD-15-0893.PubMedPubMedCentralCrossRef

17.

Esteller, M. (2011). Non-coding RNAs in human disease. Nature Reviews. Genetics, 12(12), 861–874. https://doi.org/10.1038/nrg3074.PubMedCrossRef

18.

Kozak, K. (2013). Annotation and specificity of existing genome-wide small interfering RNA libraries. Nucleic Acid Therapeutics, 23(1), 71–80. https://doi.org/10.1089/nat.2012.0387.PubMedCrossRef

19.

Mohr, S. E., & Perrimon, N. (2012). RNAi screening: new approaches, understandings, and organisms. Wiley Interdisciplinary Reviews RNA, 3(2), 145–158. https://doi.org/10.1002/wrna.110.PubMedCrossRef

20.

Rupaimoole, R., Han, H. D., Lopez-Berestein, G., & Sood, A. K. (2011). MicroRNA therapeutics: principles, expectations, and challenges. Chinese Journal of Cancer, 30(6), 368–370.PubMedPubMedCentralCrossRef

21.

Xie, W., Zhao, M., Zhou, W., Guo, L., Huang, L., Yu, W., et al. (2013). Targeting of integrin-linked kinase with small interfering RNA inhibits VEGF-induced angiogenesis in retinal endothelial cells. Ophthalmic Research, 49(3), 139–149. https://doi.org/10.1159/000345070.PubMedCrossRef

22.

Cao, Y., E, G., Wang, E., Pal, K., Dutta, S. K., Bar-Sagi, D., et al. (2012). VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Research, 72(16), 3912–3918. https://doi.org/10.1158/0008-5472.CAN-11-4058.PubMedPubMedCentralCrossRef

23.

Xi, H. Q., Zhang, K. C., Li, J. Y., Cui, J. X., Gao, Y. H., Wei, B., et al. (2017). RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer. Oncotarget, 8(19), 31581–31591. https://doi.org/10.18632/oncotarget.15770.PubMedPubMedCentralCrossRef

24.

Zhang, X. D., Wu, Q., & Yang, S. H. (2017). Effects of siRNA-mediated HIF-1alpha gene silencing on angiogenesis in osteosarcoma. Pakistan Journal of Medical Sciences, 33(2), 341–346. https://doi.org/10.12669/pjms.332.12587.PubMedPubMedCentralCrossRef

25.

Kim, M. G., Jo, S. D., Yhee, J. Y., Lee, B. S., Lee, S. J., Park, S. G., et al. (2017). Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles. Biochemical and Biophysical Research Communications, 489(1), 35–41. https://doi.org/10.1016/j.bbrc.2017.05.103.

26.

Palazzo, A. F., & Lee, E. S. (2015). Non-coding RNA: what is functional and what is junk? Frontiers in Genetics, 6, 2. https://doi.org/10.3389/fgene.2015.00002.PubMedPubMedCentralCrossRef

27.

Qu, K., Zhang, X., Lin, T., Liu, T., Wang, Z., Liu, S., et al. (2017). Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Scientific Reports, 7(1), 1692. https://doi.org/10.1038/s41598-017-01904-z.PubMedPubMedCentralCrossRef

28.

Homami, A., & Ghazi, F. (2016). MicroRNAs as biomarkers associated with bladder cancer. Medical Journal of the Islamic Republic of Iran, 30, 475.PubMedPubMedCentral

29.

Wang, L., Zheng, J., Sun, C., Wang, L., Jin, G., Xin, L., et al. (2017). MicroRNA expression levels as diagnostic biomarkers for intraductal papillary mucinous neoplasm. Oncotarget, 8(35), 58765–58770. https://doi.org/10.18632/oncotarget.17679.

30.

Yao, Y., Hu, J., Shen, Z., Yao, R., Liu, S., Li, Y., et al. (2015). MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. Journal of Cellular and Molecular Medicine, 19(4), 760–769. https://doi.org/10.1111/jcmm.12432.PubMedPubMedCentralCrossRef

31.

Lu, Y. B., Hu, J. J., Sun, W. J., Duan, X. H., & Chen, X. (2015). Prognostic value of miR-141 downregulation in gastric cancer. Genetics and Molecular Research, 14(4), 17305–17311. https://doi.org/10.4238/2015.December.16.31.PubMedCrossRef

32.

Torres, A., Torres, K., Pesci, A., Ceccaroni, M., Paszkowski, T., Cassandrini, P., et al. (2013). Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. International Journal of Cancer, 132(7), 1633–1645. https://doi.org/10.1002/ijc.27840.PubMedCrossRef

33.

Zhu, Z. M., Xu, Y. F., Su, Q. J., Du, J. D., Tan, X. L., Tu, Y. L., et al. (2014). Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma. Molecular and Cellular Biochemistry, 388(1–2), 39–49. https://doi.org/10.1007/s11010-013-1897-y.PubMedCrossRef

34.

Winther, M., Knudsen, S., Dahlgaard, J., Jensen, T., Hansen, A., Jensen, P. B., et al. (2016). Clinical impact of a novel microRNA chemo-sensitivity predictor in gastrooesophageal cancer. PLoS One, 11(2), e0148070. https://doi.org/10.1371/journal.pone.0148070.PubMedPubMedCentralCrossRef

35.

Simmer, F., Venderbosch, S., Dijkstra, J. R., Vink-Borger, E. M., Faber, C., Mekenkamp, L. J., et al. (2015). MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget, 6(26), 22996–23007. https://doi.org/10.18632/oncotarget.4035.PubMedPubMedCentralCrossRef

36.

Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews. Drug Discovery, 16(3), 203–222. https://doi.org/10.1038/nrd.2016.246.PubMedCrossRef

37.

Guan, H., Zhao, P., Dai, Z., Liu, X., & Wang, X. (2016). SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway. Tumour Biology, 37(9), 12153–12160. https://doi.org/10.1007/s13277-016-5092-0.PubMedCrossRef

38.

Martucci, N. M., Migliaccio, N., Ruggiero, I., Albano, F., Cali, G., Romano, S., et al. (2016). Nanoparticle-based strategy for personalized B-cell lymphoma therapy. International Journal of Nanomedicine, 11, 6089–6101. https://doi.org/10.2147/IJN.S118661.PubMedPubMedCentralCrossRef

39.

Liu, Y., Fei, T., Zheng, X., Brown, M., Zhang, P., Liu, X. S., et al. (2016). An integrative pharmacogenomic approach identifies two-drug combination therapies for personalized cancer medicine. Scientific Reports, 6, 22120. https://doi.org/10.1038/srep22120.PubMedPubMedCentralCrossRef

40.

Prussia, A., Thepchatri, P., Snyder, J. P., & Plemper, R. K. (2011). Systematic approaches towards the development of host-directed antiviral therapeutics. International Journal of Molecular Sciences, 12(6), 4027–4052. https://doi.org/10.3390/ijms12064027.PubMedPubMedCentralCrossRef

41.

Voinnet, O. (2005). Induction and suppression of RNA silencing: insights from viral infections. Nature Reviews. Genetics, 6(3), 206–220. https://doi.org/10.1038/nrg1555.PubMedCrossRef

42.

Blake, S. J., Bokhari, F. F., & McMillan, N. A. (2012). RNA interference for viral infections. Current Drug Targets, 13(11), 1411–1420.PubMedCrossRef

43.

Choi, J. G., Bharaj, P., Abraham, S., Ma, H., Yi, G., Ye, C., et al. (2015). Multiplexing seven miRNA-based shRNAs to suppress HIV replication. Molecular Therapy, 23(2), 310–320. https://doi.org/10.1038/mt.2014.205.PubMedCrossRef

44.

Nathans, R., Chu, C. Y., Serquina, A. K., Lu, C. C., Cao, H., & Rana, T. M. (2009). Cellular microRNA and P bodies modulate host-HIV-1 interactions. Molecular Cell, 34(6), 696–709. https://doi.org/10.1016/j.molcel.2009.06.003.PubMedPubMedCentralCrossRef

45.

Tchurikov, N. A., Fedoseeva, D. M., Gashnikova, N. M., Sosin, D. V., Gorbacheva, M. A., Alembekov, I. R., et al. (2016). Conserved sequences in the current strains of HIV-1 subtype A in Russia are effectively targeted by artificial RNAi in vitro. Gene, 583(1), 78–83. https://doi.org/10.1016/j.gene.2016.03.001.PubMedCrossRef

46.

Kravatsky, Y. V., Chechetkin, V. R., Fedoseeva, D. M., Gorbacheva, M. A., Kretova, O. V., & Tchurikov, N. A. (2016). Mutation frequencies in HIV-1 subtype-A genome in regions containing efficient RNAi targets. Molekuliarnaia Biologiia (Mosk), 50(3), 480–485. https://doi.org/10.7868/S0026898416020117.

47.

Cornu, T. I., Mussolino, C., Bloom, K., & Cathomen, T. (2015). Editing CCR5: a novel approach to HIV gene therapy. Advances in Experimental Medicine and Biology, 848, 117–130. https://doi.org/10.1007/978-1-4939-2432-5_6.PubMedCrossRef

48.

Zhang, W., Yang, H., Kong, X., Mohapatra, S., San Juan-Vergara, H., Hellermann, G., et al. (2005). Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nature Medicine, 11(1), 56–62. https://doi.org/10.1038/nm1174.PubMedCrossRef

49.

DeVincenzo, J., Cehelsky, J. E., Alvarez, R., Elbashir, S., Harborth, J., Toudjarska, I., et al. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Research, 77(3), 225–231. https://doi.org/10.1016/j.antiviral.2007.11.009.PubMedCrossRef

50.

Ballarin-Gonzalez, B., Thomsen, T. B., & Howard, K. A. (2013). Clinical translation of RNAi-based treatments for respiratory diseases. Drug Delivery and Translational Research, 3(1), 84–99. https://doi.org/10.1007/s13346-012-0098-7.PubMedCrossRef

51.

Barik, S., & Lu, P. (2015). Therapy of respiratory viral infections with intranasal siRNAs. Methods in Molecular Biology, 1218, 251–262. https://doi.org/10.1007/978-1-4939-1538-5_14.PubMedCrossRef

52.

Malekshahi, S. S., Salimi, V., Arefian, E., Fatemi-Nasab, G., Adjaminejad-Fard, S., Yavarian, J., et al. (2016). Inhibition of respiratory syncytial virus replication by simultaneous targeting of mRNA and genomic RNA using dual-targeting siRNAs. Molecular Biotechnology, 58(11), 767–775. https://doi.org/10.1007/s12033-016-9976-4.PubMedCrossRef

53.

Gane, E. J. (2017). Future anti-HBV strategies. Liver International, 37(Suppl 1), 40–44. https://doi.org/10.1111/liv.13304.PubMedCrossRef

54.

Ebert, G., Poeck, H., Lucifora, J., Baschuk, N., Esser, K., Esposito, I., et al. (2011). 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology, 141(2), 696–706, 706 e691–693. https://doi.org/10.1053/j.gastro.2011.05.001.PubMedCrossRef

55.

Yamamoto, N., Sato, Y., Munakata, T., Kakuni, M., Tateno, C., Sanada, T., et al. (2016). Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. Journal of Hepatology, 64(3), 547–555. https://doi.org/10.1016/j.jhep.2015.10.014.PubMedCrossRef

56.

Lee, C. H., Kim, J. H., & Lee, S. W. (2016). The role of microRNA in pathogenesis and as markers of HCV chronic infection. Current Drug Targets, 18(7), 756–765. https://doi.org/10.2174/1389450117666160401125213.

57.

Zekri, A. N., Youssef, A. S., El-Desouky, E. D., Ahmed, O. S., Lotfy, M. M., Nassar, A. A., et al. (2016). Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biology, 37(9), 12273–12286. https://doi.org/10.1007/s13277-016-5097-8.PubMedCrossRef

58.

Shaker, O. G., & Senousy, M. A. (2017). Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients. Journal of Viral Hepatitis, 24(8), 636–644. https://doi.org/10.1111/jvh.12696.

59.

Jiao, X., Fan, Z., Chen, H., He, P., Li, Y., Zhang, Q., et al. (2017). Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. Journal of Medical Virology, 89(9),1597–1605. https://doi.org/10.1002/jmv.24829.

60.

Luna, J. M., Scheel, T. K., Danino, T., Shaw, K. S., Mele, A., Fak, J. J., et al. (2015). Hepatitis C virus RNA functionally sequesters miR-122. Cell, 160(6), 1099–1110. https://doi.org/10.1016/j.cell.2015.02.025.PubMedPubMedCentralCrossRef

61.

Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., et al. (2013). Treatment of HCV infection by targeting microRNA. The New England Journal of Medicine, 368(18), 1685–1694. https://doi.org/10.1056/NEJMoa1209026.PubMedCrossRef

62.

Hoelscher, S. C., Doppler, S. A., Dressen, M., Lahm, H., Lange, R., & Krane, M. (2017). MicroRNAs: pleiotropic players in congenital heart disease and regeneration. Journal of Thoracic Disease, 9(Suppl 1), S64–S81. https://doi.org/10.21037/jtd.2017.03.149.PubMedPubMedCentralCrossRef

63.

Kwekkeboom, R. F., Lei, Z., Doevendans, P. A., Musters, R. J., & Sluijter, J. P. (2014). Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clinical Science (London, England), 127(6), 351–365. https://doi.org/10.1042/CS20140005.CrossRef

64.

Tadin-Strapps, M., Robinson, M., Le Voci, L., Andrews, L., Yendluri, S., Williams, S., et al. (2015). Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis. Journal of Cardiovascular Translational Research, 8(1), 44–53. https://doi.org/10.1007/s12265-014-9605-1.PubMedCrossRef

65.

Zhou, F., Jia, X., Yang, Q., Yang, Y., Zhao, Y., Fan, Y., et al. (2016). Targeted delivery of microRNA-126 to vascular endothelial cells via REDV peptide modified PEG-trimethyl chitosan. Biomaterials Science, 4(5), 849–856. https://doi.org/10.1039/c5bm00629e.PubMedCrossRef

66.

Zhou, F., Jia, X., Yang, Y., Yang, Q., Gao, C., Hu, S., et al. (2016). Nanofiber-mediated microRNA-126 delivery to vascular endothelial cells for blood vessel regeneration. Acta Biomaterialia, 43, 303–313. https://doi.org/10.1016/j.actbio.2016.07.048.PubMedCrossRef

67.

Navickas, R., Gal, D., Laucevicius, A., Taparauskaite, A., Zdanyte, M., & Holvoet, P. (2016). Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovascular Research, 111(4), 322–337. https://doi.org/10.1093/cvr/cvw174.PubMedPubMedCentralCrossRef

68.

Kasner, M., Gast, M., Galuszka, O., Stroux, A., Rutschow, S., Wang, X., et al. (2016). Circulating exosomal microRNAs predict functional recovery after MitraClip repair of severe mitral regurgitation. International Journal of Cardiology, 215, 402–405. https://doi.org/10.1016/j.ijcard.2016.04.018.PubMedCrossRef

69.

Eliasson, L., & Esguerra, J. L. (2014). Role of non-coding RNAs in pancreatic beta-cell development and physiology. Acta Physiologica (Oxford, England), 211(2), 273–284. https://doi.org/10.1111/apha.12285.CrossRef

70.

Guglielmi, V., D'Adamo, M., Menghini, R., Cardellini, M., Gentileschi, P., Federici, M., et al. (2017). MicroRNA 21 is up-regulated in adipose tissue of obese diabetic subjects. Nutrition Healthy Aging, 4(2), 141–145. https://doi.org/10.3233/NHA-160020.PubMedPubMedCentralCrossRef

71.

Kaviani, M., Azarpira, N., Karimi, M. H., & Al-Abdullah, I. (2016). The role of microRNAs in islet beta-cell development. Cell Biology International, 40(12), 1248–1255. https://doi.org/10.1002/cbin.10691.PubMedCrossRef

72.

Pishavar, E., & Behravan, J. (2017). miR-126 as a therapeutic agent for diabetes mellitus. Current Pharmaceutical Design, 23(22),3309–3314. https://doi.org/10.2174/1381612823666170424120121.

73.

de Gonzalo-Calvo, D., van der Meer, R. W., Rijzewijk, L. J., Smit, J. W., Revuelta-Lopez, E., Nasarre, L., et al. (2017). Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Scientific Reports, 7(1), 47. https://doi.org/10.1038/s41598-017-00070-6.PubMedPubMedCentralCrossRef

74.

Zou, H. L., Wang, Y., Gang, Q., Zhang, Y., & Sun, Y. (2017). Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 255(6), 1159–1166. https://doi.org/10.1007/s00417-017-3638-5.

75.

Willeit, P., Skroblin, P., Moschen, A. R., Yin, X., Kaudewitz, D., Zampetaki, A., et al. (2017). Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes, 66(2), 347–357. https://doi.org/10.2337/db16-0731.PubMedCrossRef

76.

Zhu, Y., Tian, F., Li, H., Zhou, Y., Lu, J., & Ge, Q. (2015). Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. International Journal of Gynaecology and Obstetrics, 130(1), 49–53. https://doi.org/10.1016/j.ijgo.2015.01.010.PubMedCrossRef

77.

Sam, M. R., Azadbakhsh, A. S., Farokhi, F., Rezazadeh, K., Sam, S., Zomorodipour, A., et al. (2016). Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids. Biologicals, 44(3), 170–177. https://doi.org/10.1016/j.biologicals.2016.01.002.PubMedCrossRef

78.

Wang, W., Li, C., Li, W., Kong, L., Qian, A., Hu, N., et al. (2014). MiR-150 enhances the motility of EPCs in vitro and promotes EPCs homing and thrombus resolving in vivo. Thrombosis Research, 133(4), 590–598. https://doi.org/10.1016/j.thromres.2013.12.038.PubMedCrossRef

79.

Huleihel, L., Sellares, J., Cardenes, N., Alvarez, D., Faner, R., Sakamoto, K., et al. (2017). Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. American Journal of Physiology Lung Cellular and Molecular Physiology, 313(1), L92–L103. https://doi.org/10.1152/ajplung.00323.2016.

80.

Qu, Y., Zhang, Q., Cai, X., Li, F., Ma, Z., Xu, M., et al. (2017). Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. Journal of Cellular and Molecular Medicine, 21(10), 2491–2502. https://doi.org/10.1111/jcmm.13170.

81.

Wei, G. J., An, G., Shi, Z. W., Wang, K. F., Guan, Y., Wang, Y. S., et al. (2017). Suppression of microRNA-383 enhances therapeutic potential of human bone-marrow-derived mesenchymal stem cells in treating spinal cord injury via GDNF. Cellular Physiology and Biochemistry, 41(4), 1435–1444. https://doi.org/10.1159/000468057.PubMedCrossRef

82.

Pan, Y., Shu, X., Sun, L., Yu, L., Sun, L., Yang, Z., et al. (2017). miR196a5p modulates gastric cancer stem cell characteristics by targeting Smad4. International Journal of Oncology, 50(6), 1965–1976. https://doi.org/10.3892/ijo.2017.3965.

83.

Wang, L., Wang, J., Li, Z., Liu, Y., Jiang, M., Li, Y., et al. (2016). Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells. Tumour Biology, 37(6), 7213–7227. https://doi.org/10.1007/s13277-015-4577-6.PubMedCrossRef

84.

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009). Knocking down barriers: advances in siRNA delivery. Nature Reviews. Drug Discovery, 8(2), 129–138. https://doi.org/10.1038/nrd2742.PubMedCrossRef

85.

Hickerson, R. P., Vlassov, A. V., Wang, Q., Leake, D., Ilves, H., Gonzalez-Gonzalez, E., et al. (2008). Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides, 18(4), 345–354. https://doi.org/10.1089/oli.2008.0149.PubMedPubMedCentralCrossRef

86.

Sarett, S. M., Kilchrist, K. V., Miteva, M., & Duvall, C. L. (2015). Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles. Journal of Biomedical Materials Research. Part A, 103(9), 3107–3116. https://doi.org/10.1002/jbm.a.35413.PubMedPubMedCentralCrossRef

87.

Bramsen, J. B., & Kjems, J. (2010). Chemical modification of small interfering RNA. Methods in Molecular Biology, 721, 77–103. https://doi.org/10.1007/978-1-61779-037-9_5.CrossRef

88.

Lee, S. J., Son, S., Yhee, J. Y., Choi, K., Kwon, I. C., Kim, S. H., et al. (2013). Structural modification of siRNA for efficient gene silencing. Biotechnology Advances, 31(5), 491–503. https://doi.org/10.1016/j.biotechadv.2012.09.002.PubMedCrossRef

89.

Tokatlian, T., & Segura, T. (2010). siRNA applications in nanomedicine. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 2(3), 305–315. https://doi.org/10.1002/wnan.81.PubMedPubMedCentralCrossRef

90.

Behlke, M. A. (2008). Chemical modification of siRNAs for in vivo use. Oligonucleotides, 18(4), 305–319. https://doi.org/10.1089/oli.2008.0164.PubMedCrossRef

91.

Bramsen, J. B., & Kjems, J. (2013). Engineering small interfering RNAs by strategic chemical modification. Methods in Molecular Biology, 942, 87–109. https://doi.org/10.1007/978-1-62703-119-6_5.PubMedCrossRef

92.

Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L. (2010). Delivery of siRNA therapeutics: barriers and carriers. The AAPS Journal, 12(4), 492–503. https://doi.org/10.1208/s12248-010-9210-4.PubMedPubMedCentralCrossRef

93.

Danquah, M. K., Zhang, X. A., & Mahato, R. I. (2011). Extravasation of polymeric nanomedicines across tumor vasculature. Advanced Drug Delivery Reviews, 63(8), 623–639. https://doi.org/10.1016/j.addr.2010.11.005.PubMedCrossRef

94.

Raouane, M., Desmaele, D., Urbinati, G., Massaad-Massade, L., & Couvreur, P. (2012). Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjugate Chemistry, 23(6), 1091–1104. https://doi.org/10.1021/bc200422w.PubMedCrossRef

95.

Layek, B., Lipp, L., & Singh, J. (2015). Cell penetrating peptide conjugated chitosan for enhanced delivery of nucleic acid. International Journal of Molecular Sciences, 16(12), 28912–28930. https://doi.org/10.3390/ijms161226142.PubMedPubMedCentralCrossRef

96.

O'Loughlin, A. J., Mager, I., de Jong, O. G., Varela, M. A., Schiffelers, R. M., El Andaloussi, S., et al. (2017). Functional delivery of lipid-conjugated siRNA by extracellular vesicles. Molecular Therapy, 25(7), 1580–1587. https://doi.org/10.1016/j.ymthe.2017.03.021.

97.

Powell, D., Chandra, S., Dodson, K., Shaheen, F., Wiltz, K., Ireland, S., et al. (2017). Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. European Journal of Pharmaceutics and Biopharmaceutics, 114, 108–118. https://doi.org/10.1016/j.ejpb.2017.01.011.PubMedCrossRef

98.

Bruck, J., Pascolo, S., Fuchs, K., Kellerer, C., Glocova, I., Geisel, J., et al. (2015). Cholesterol modification of p40-specific small interfering RNA enables therapeutic targeting of dendritic cells. Journal of Immunology, 195(5), 2216–2223. https://doi.org/10.4049/jimmunol.1402989.CrossRef

99.

Wang, Y., Chen, X., Tian, B., Liu, J., Yang, L., Zeng, L., et al. (2017). Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics, 7(5), 1360–1372. https://doi.org/10.7150/thno.16532.PubMedPubMedCentralCrossRef

100.

Akhtar, S., & Benter, I. F. (2007). Nonviral delivery of synthetic siRNAs in vivo. The Journal of Clinical Investigation, 117(12), 3623–3632. https://doi.org/10.1172/JCI33494.PubMedPubMedCentralCrossRef

101.

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., et al. (2010). Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 28(2), 172–176. https://doi.org/10.1038/nbt.1602.PubMedCrossRef

102.

Meng, Z., Zhang, X., Wu, J., Pei, R., Xu, Y., Yang, D., et al. (2013). RNAi induces innate immunity through multiple cellular signaling pathways. PLoS One, 8(5), e64708. https://doi.org/10.1371/journal.pone.0064708.PubMedPubMedCentralCrossRef

103.

Meng, Z., & Lu, M. (2017). RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Frontiers in Immunology, 8, 331. https://doi.org/10.3389/fimmu.2017.00331.PubMedPubMedCentral

104.

Jackson, A. L., & Linsley, P. S. (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature Reviews. Drug Discovery, 9(1), 57–67. https://doi.org/10.1038/nrd3010.PubMedCrossRef

105.

Schluep, T., Lickliter, J., Hamilton, J., Lewis, D. L., Lai, C. L., Lau, J. Y., et al. (2017). Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. Clinical Pharmacol Drug Development, 6(4), 350–362.https://doi.org/10.1002/cpdd.318.

106.

Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y. K., Stoudemire, J., et al. (2017). Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs, 35(2), 180–188. https://doi.org/10.1007/s10637-016-0407-y.PubMedCrossRef

107.

Valenzuela, R. A., Suter, S. R., Ball-Jones, A. A., Ibarra-Soza, J. M., Zheng, Y., & Beal, P. A. (2015). Base modification strategies to modulate immune stimulation by an siRNA. Chembiochem, 16(2), 262–267. https://doi.org/10.1002/cbic.201402551.PubMedCrossRef

108.

Grimm, D. (2009). Small silencing RNAs: state-of-the-art. Advanced Drug Delivery Reviews, 61(9), 672–703. https://doi.org/10.1016/j.addr.2009.05.002.PubMedCrossRef

109.

Giacca, M., & Zacchigna, S. (2012). Virus-mediated gene delivery for human gene therapy. Journal of Controlled Release, 161(2), 377–388. https://doi.org/10.1016/j.jconrel.2012.04.008.PubMedCrossRef

110.

Keller, M. (2009). Nanomedicinal delivery approaches for therapeutic siRNA. International Journal of Pharmaceutics, 379(2), 210–211. https://doi.org/10.1016/j.ijpharm.2009.03.038.PubMedCrossRef

111.

Rezaee, M., Oskuee, R. K., Nassirli, H., & Malaekeh-Nikouei, B. (2016). Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. Journal of Controlled Release, 236, 1–14. https://doi.org/10.1016/j.jconrel.2016.06.023.PubMedCrossRef

112.

Chapoy-Villanueva, H., Martinez-Carlin, I., Lopez-Berestein, G., & Chavez-Reyes, A. (2015). Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. Journal of BUON, 20(6), 1471–1479.PubMed

113.

Dunne, P. D., Dasgupta, S., Blayney, J. K., McArt, D. G., Redmond, K. L., Weir, J. A., et al. (2016). EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clinical Cancer Research, 22(1), 230–242. https://doi.org/10.1158/1078-0432.CCR-15-0603.PubMedCrossRef

114.

Song, W., Hwang, Y., Youngblood, V. M., Cook, R. S., Balko, J. M., Chen, J., et al. (2017). Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene, 36(40), 5620–5630. https://doi.org/10.1038/onc.2017.170.

115.

Landen Jr., C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., et al. (2005). Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Research, 65(15), 6910–6918. https://doi.org/10.1158/0008-5472.CAN-05-0530.PubMedCrossRef

116.

Wagner, M. J., Mitra, R., McArthur, M. J., Baze, W., Barnhart, K., Wu, S. Y., et al. (2017). Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Molecular Cancer Therapeutics, 16(6), 1114–1123. https://doi.org/10.1158/1535-7163.MCT-16-0541.PubMedCrossRef

117.

Fan, Y., Chen, C., Huang, Y., Zhang, F., & Lin, G. (2017). Study of the pH-sensitive mechanism of tumor-targeting liposomes. Colloids and Surfaces. B, Biointerfaces, 151, 19–25. https://doi.org/10.1016/j.colsurfb.2016.11.042.PubMedCrossRef

118.

Gujrati, M., Vaidya, A. M., Mack, M., Snyder, D., Malamas, A., & Lu, Z. R. (2016). Targeted dual pH-sensitive lipid ECO/siRNA self-assembly nanoparticles facilitate in vivo cytosolic sieIF4E delivery and overcome paclitaxel resistance in breast cancer therapy. Advanced Healthcare Materials, 5(22), 2882–2895. https://doi.org/10.1002/adhm.201600677.PubMedPubMedCentralCrossRef

119.

Iversen, F., Yang, C., Dagnaes-Hansen, F., Schaffert, D. H., Kjems, J., & Gao, S. (2013). Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics, 3(3), 201–209. https://doi.org/10.7150/thno.5743.PubMedPubMedCentralCrossRef

120.

Nag, O. K., & Awasthi, V. (2013). Surface engineering of liposomes for stealth behavior. Pharmaceutics, 5(4), 542–569. https://doi.org/10.3390/pharmaceutics5040542.PubMedPubMedCentralCrossRef

121.

Chauhan, H., Mohapatra, S., Munt, D. J., Chandratre, S., & Dash, A. (2016). Physical-chemical characterization and formulation considerations for solid lipid nanoparticles. AAPS PharmSciTech, 17(3), 640–651. https://doi.org/10.1208/s12249-015-0394-x.PubMedCrossRef

122.

Botto, C., Mauro, N., Amore, E., Martorana, E., Giammona, G., & Bondi, M. L. (2017). Surfactant effect on the physicochemical characteristics of cationic solid lipid nanoparticles. International Journal of Pharmaceutics, 516(1–2), 334–341. https://doi.org/10.1016/j.ijpharm.2016.11.052.PubMedCrossRef

123.

Lobovkina, T., Jacobson, G. B., Gonzalez-Gonzalez, E., Hickerson, R. P., Leake, D., Kaspar, R. L., et al. (2011). In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano, 5(12), 9977–9983. https://doi.org/10.1021/nn203745n.PubMedPubMedCentralCrossRef

124.

Yu, Y. H., Kim, E., Park, D. E., Shim, G., Lee, S., Kim, Y. B., et al. (2012). Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. European Journal of Pharmaceutics and Biopharmaceutics, 80(2), 268–273. https://doi.org/10.1016/j.ejpb.2011.11.002.PubMedCrossRef

125.

Jin, J., Bae, K. H., Yang, H., Lee, S. J., Kim, H., Kim, Y., et al. (2011). In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjugate Chemistry, 22(12), 2568–2572. https://doi.org/10.1021/bc200406n.PubMedCrossRef

126.

Xue, H. Y., Tran, N., & Wong, H. L. (2016). A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy. European Journal of Pharmaceutics and Biopharmaceutics, 108, 68–75. https://doi.org/10.1016/j.ejpb.2016.08.014.PubMedPubMedCentralCrossRef

127.

Naseri, N., Valizadeh, H., & Zakeri-Milani, P. (2015). Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull, 5(3), 305–313. https://doi.org/10.15171/apb.2015.043.PubMedPubMedCentralCrossRef

128.

Han, Y., Li, Y., Zhang, P., Sun, J., Li, X., Sun, X., et al. (2016). Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharmaceutical Development and Technology, 21(3), 277–281. https://doi.org/10.3109/10837450.2014.996900.PubMedCrossRef

129.

Shao, Z., Shao, J., Tan, B., Guan, S., Liu, Z., Zhao, Z., et al. (2015). Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. International Journal of Nanomedicine, 10, 1223–1233. https://doi.org/10.2147/IJN.S77837.PubMedPubMedCentralCrossRef

130.

Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O. B., & Minko, T. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. Journal of Controlled Release, 171(3), 349–357. https://doi.org/10.1016/j.jconrel.2013.04.018.PubMedPubMedCentralCrossRef

131.

Xue, H. Y., & Wong, H. L. (2011). Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials, 32(10), 2662–2672. https://doi.org/10.1016/j.biomaterials.2010.12.029.PubMedCrossRef

132.

Breunig, M., Lungwitz, U., Liebl, R., & Goepferich, A. (2007). Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proceedings of the National Academy of Sciences of the United States of America, 104(36), 14454–14459. https://doi.org/10.1073/pnas.0703882104.PubMedPubMedCentralCrossRef

133.

Dominska, M., & Dykxhoorn, D. M. (2010). Breaking down the barriers: siRNA delivery and endosome escape. Journal of Cell Science, 123(Pt 8), 1183–1189. https://doi.org/10.1242/jcs.066399.PubMedCrossRef

134.

Gomes-da-Silva, L. C., Fonseca, N. A., Moura, V., Pedroso de Lima, M. C., Simoes, S., & Moreira, J. N. (2012). Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Accounts of Chemical Research, 45(7), 1163–1171. https://doi.org/10.1021/ar300048p.PubMedCrossRef

135.

Tros de Ilarduya, C., Sun, Y., & Duzgunes, N. (2010). Gene delivery by lipoplexes and polyplexes. European Journal of Pharmaceutical Sciences, 40(3), 159–170. https://doi.org/10.1016/j.ejps.2010.03.019.PubMedCrossRef

136.

Yang, C., Gao, S., Dagnaes-Hansen, F., Jakobsen, M., & Kjems, J. (2017). Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo. ACS Applied Materials & Interfaces, 9(14), 12203–12216. https://doi.org/10.1021/acsami.6b16556.CrossRef

137.

Sun, P., Huang, W., Kang, L., Jin, M., Fan, B., Jin, H., et al. (2017). siRNA-loaded poly(histidine-arginine)6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis. International Journal of Nanomedicine, 12, 3221–3234. https://doi.org/10.2147/IJN.S129436.PubMedPubMedCentralCrossRef

138.

Gu, J., Al-Bayati, K., & Ho, E. A. (2017). Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Delivery and Translational Research, 7(4), 497–506. https://doi.org/10.1007/s13346-017-0368-5.

139.

Gao, L. Y., Liu, X. Y., Chen, C. J., Wang, J. C., Feng, Q., Yu, M. Z., et al. (2014). Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials, 35(6), 2066–2078. https://doi.org/10.1016/j.biomaterials.2013.11.046.PubMedCrossRef

140.

Zhao, X., Li, F., Li, Y., Wang, H., Ren, H., Chen, J., et al. (2015). Co-delivery of HIF1alpha siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials, 46, 13–25. https://doi.org/10.1016/j.biomaterials.2014.12.028.PubMedCrossRef

141.

Yang, X. Z., Dou, S., Wang, Y. C., Long, H. Y., Xiong, M. H., Mao, C. Q., et al. (2012). Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano, 6(6), 4955–4965. https://doi.org/10.1021/nn300500u.PubMedCrossRef

142.

Li, Y., Huang, X., Lee, R. J., Qi, Y., Wang, K., Hao, F., et al. (2016). Synthesis of polymer-lipid nanoparticles by microfluidic focusing for siRNA delivery. Molecules, 21(10). https://doi.org/10.3390/molecules21101314.

143.

Ki, M. H., Kim, J. E., Lee, Y. N., Noh, S. M., An, S. W., Cho, H. J., et al. (2014). Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy. Pharmaceutical Research, 31(12), 3323–3334. https://doi.org/10.1007/s11095-014-1422-3.PubMedCrossRef

144.

Zhong, J., Huang, H. L., Li, J., Qian, F. C., Li, L. Q., Niu, P. P., et al. (2015). Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells. Hepatobiliary & Pancreatic Diseases International, 14(1), 82–89.CrossRef

145.

Ju, Z., Ma, J., Wang, C., Yu, J., Qiao, Y., & Hei, F. (2017). Exosomes from iPSCs delivering siRNA attenuate intracellular adhesion molecule-1 expression and neutrophils adhesion in pulmonary microvascular endothelial cells. Inflammation, 40(2), 486–496. https://doi.org/10.1007/s10753-016-0494-0.PubMedCrossRef

146.

Thery, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews. Immunology, 2(8), 569–579. https://doi.org/10.1038/nri855.PubMedCrossRef

147.

Lee, H. M., Choi, E. J., Kim, J. H., Kim, T. D., Kim, Y. K., Kang, C., et al. (2010). A membranous form of ICAM-1 on exosomes efficiently blocks leukocyte adhesion to activated endothelial cells. Biochemical and Biophysical Research Communications, 397(2), 251–256. https://doi.org/10.1016/j.bbrc.2010.05.094.PubMedCrossRef

148.

Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., et al. (2015). Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharmaceutical Research, 32(6), 2003–2014. https://doi.org/10.1007/s11095-014-1593-y.PubMedPubMedCentralCrossRef

149.

Yim, N., Ryu, S. W., Choi, K., Lee, K. R., Lee, S., Choi, H., et al. (2016). Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nature Communications, 7, 12277. https://doi.org/10.1038/ncomms12277.PubMedPubMedCentralCrossRef

150.

Kooijmans, S. A., Vader, P., van Dommelen, S. M., van Solinge, W. W., & Schiffelers, R. M. (2012). Exosome mimetics: a novel class of drug delivery systems. International Journal of Nanomedicine, 7, 1525–1541. https://doi.org/10.2147/IJN.S29661.PubMedPubMedCentral

151.

Ha, D., Yang, N., & Nadithe, V. (2016). Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharmaceutica Sinica B, 6(4), 287–296. https://doi.org/10.1016/j.apsb.2016.02.001.PubMedPubMedCentralCrossRef

152.

Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., et al. (2014). A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials, 35(7), 2383–2390. https://doi.org/10.1016/j.biomaterials.2013.11.083.PubMedCrossRef

153.

Cooper, J. M., Wiklander, P. B., Nordin, J. Z., Al-Shawi, R., Wood, M. J., Vithlani, M., et al. (2014). Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 29(12), 1476–1485. https://doi.org/10.1002/mds.25978.PubMedPubMedCentralCrossRef

154.

Sterzenbach, U., Putz, U., Low, L. H., Silke, J., Tan, S. S., & Howitt, J. (2017). Engineered exosomes as vehicles for biologically active proteins. Molecular Therapy, 25(6), 1269–1278. https://doi.org/10.1016/j.ymthe.2017.03.030.

155.

Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., & Sun, D. (2017). Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacologica Sinica, 38(6), 754–763. https://doi.org/10.1038/aps.2017.12.

156.

Ohno, S. I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., et al. (2013). Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Molecular Therapy, 21(1), 185–191. https://doi.org/10.1038/mt.2012.180.PubMedCrossRef

157.

Lacko, A. G., Sabnis, N. A., Nagarajan, B., & McConathy, W. J. (2015). HDL as a drug and nucleic acid delivery vehicle. Frontiers in Pharmacology, 6, 247. https://doi.org/10.3389/fphar.2015.00247.PubMedPubMedCentralCrossRef

158.

Mooberry, L. K., Sabnis, N. A., Panchoo, M., Nagarajan, B., & Lacko, A. G. (2016). Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging. Frontiers in Pharmacology, 7, 466. https://doi.org/10.3389/fphar.2016.00466.PubMedPubMedCentralCrossRef

159.

Shahzad, M. M., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., et al. (2011). Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia, 13(4), 309–319.PubMedPubMedCentralCrossRef

160.

Ding, Y., Wang, W., Feng, M., Wang, Y., Zhou, J., Ding, X., et al. (2012). A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials, 33(34), 8893–8905. https://doi.org/10.1016/j.biomaterials.2012.08.057.PubMedCrossRef

161.

Pan, B., Ren, H., Lv, X., Zhao, Y., Yu, B., He, Y., et al. (2012). Hypochlorite-induced oxidative stress elevates the capability of HDL in promoting breast cancer metastasis. Journal of Translational Medicine, 10, 65. https://doi.org/10.1186/1479-5876-10-65.PubMedPubMedCentralCrossRef

162.

Tang, J., Kuai, R., Yuan, W., Drake, L., Moon, J. J., & Schwendeman, A. (2017). Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting. Nanomedicine, 13(6), 1869–1878.https://doi.org/10.1016/j.nano.2017.04.009.

163.

Lakhin, A. V., Tarantul, V. Z., & Gening, L. V. (2013). Aptamers: problems, solutions and prospects. Acta Naturae, 5(4), 34–43.PubMedPubMedCentral

164.

Li, X., Zhao, Q., & Qiu, L. (2013). Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. Journal of Controlled Release, 171(2), 152–162. https://doi.org/10.1016/j.jconrel.2013.06.006.PubMedCrossRef

165.

Bagalkot, V., & Gao, X. (2011). siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano, 5(10), 8131–8139. https://doi.org/10.1021/nn202772p.PubMedPubMedCentralCrossRef

166.

Lai, W. Y., Wang, W. Y., Chang, Y. C., Chang, C. J., Yang, P. C., & Peck, K. (2014). Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials, 35(9), 2905–2914. https://doi.org/10.1016/j.biomaterials.2013.12.054.PubMedCrossRef

167.

Li, L., Hou, J., Liu, X., Guo, Y., Wu, Y., Zhang, L., et al. (2014). Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials, 35(12), 3840–3850. https://doi.org/10.1016/j.biomaterials.2014.01.019.PubMedCrossRef

168.

Binzel, D. W., Shu, Y., Li, H., Sun, M., Zhang, Q., Shu, D., et al. (2016). Specific delivery of MiRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Molecular Therapy, 24(7), 1267–1277. https://doi.org/10.1038/mt.2016.85.PubMedPubMedCentralCrossRef

169.

Lee, S. K., Siefert, A., Beloor, J., Fahmy, T. M., & Kumar, P. (2012). Cell-specific siRNA delivery by peptides and antibodies. Methods in Enzymology, 502, 91–122. https://doi.org/10.1016/B978-0-12-416039-2.00005-7.PubMedCrossRef

170.

Rengaswamy, V., Zimmer, D., Suss, R., & Rossler, J. (2016). RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. Journal of Controlled Release, 235, 319–327. https://doi.org/10.1016/j.jconrel.2016.05.063.PubMedCrossRef

171.

Palanca-Wessels, M. C., Booth, G. C., Convertine, A. J., Lundy, B. B., Berguig, G. Y., Press, M. F., et al. (2016). Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget, 7(8), 9561–9575. https://doi.org/10.18632/oncotarget.7076.PubMedPubMedCentralCrossRef

172.

Guo, J., Russell, E. G., Darcy, R., Cotter, T. G., McKenna, S. L., Cahill, M. R., et al. (2017). Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: Physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy. Molecular Pharmaceutics, 14(3), 940–952. https://doi.org/10.1021/acs.molpharmaceut.6b01150.PubMedCrossRef

173.

Jones, S. K., Lizzio, V., & Merkel, O. M. (2016). Folate receptor targeted delivery of siRNA and paclitaxel to ovarian cancer cells via folate conjugated triblock copolymer to overcome TLR4 driven chemotherapy resistance. Biomacromolecules, 17(1), 76–87. https://doi.org/10.1021/acs.biomac.5b01189.PubMedCrossRef

174.

Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013). Delivery materials for siRNA therapeutics. Nature Materials, 12(11), 967–977. https://doi.org/10.1038/nmat3765.PubMedCrossRef

175.

Wang, J., Mi, P., Lin, G., Wang, Y. X., Liu, G., & Chen, X. (2016). Imaging-guided delivery of RNAi for anticancer treatment. Advanced Drug Delivery Reviews, 104, 44–60. https://doi.org/10.1016/j.addr.2016.01.008.PubMedPubMedCentralCrossRef

176.

Wang, F., Song, X., Li, X., Xin, J., Wang, S., Yang, W., et al. (2013). Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS One, 8(4), e61792. https://doi.org/10.1371/journal.pone.0061792.PubMedPubMedCentralCrossRef

177.

Lin, Q., Huang, H., Chen, J., & Zheng, G. (2016). Using fluorescence imaging to track drug delivery and guide treatment planning in vivo. Methods in Molecular Biology, 1444, 153–166. https://doi.org/10.1007/978-1-4939-3721-9_14.PubMedCrossRef

178.

Sita, T. L., Kouri, F. M., Hurley, L. A., Merkel, T. J., Chalastanis, A., May, J. L., et al. (2017). Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 114(16), 4129–4134. https://doi.org/10.1073/pnas.1702736114.PubMedPubMedCentralCrossRef

179.

Chen, Y., Wang, X., Liu, T., Zhang, D. S., Wang, Y., Gu, H., et al. (2015). Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy. International Journal of Nanomedicine, 10, 2579–2594. https://doi.org/10.2147/IJN.S78774.PubMedPubMedCentral

180.

Veiseh, O., Kievit, F. M., Fang, C., Mu, N., Jana, S., Leung, M. C., et al. (2010). Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials, 31(31), 8032–8042. https://doi.org/10.1016/j.biomaterials.2010.07.016.PubMedPubMedCentralCrossRef

181.

Wang, P., & Moore, A. (2016). In vivo magnetic resonance imaging of small interfering RNA nanodelivery to pancreatic islets. Methods in Molecular Biology, 1372, 25–36. https://doi.org/10.1007/978-1-4939-3148-4_2.PubMedCrossRef

182.

Gottesman, M. M., & Ling, V. (2006). The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Letters, 580(4), 998–1009. https://doi.org/10.1016/j.febslet.2005.12.060.PubMedCrossRef

183.

Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013). Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One, 8(1), e55509. https://doi.org/10.1371/journal.pone.0055509.PubMedPubMedCentralCrossRef

184.

Higgins, C. F. (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature, 446(7137), 749–757. https://doi.org/10.1038/nature05630.PubMedCrossRef

185.

Takara, K., Sakaeda, T., & Okumura, K. (2006). An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Current Pharmaceutical Design, 12(3), 273–286.PubMedCrossRef

186.

Palmeira, A., Vasconcelos, M. H., Paiva, A., Fernandes, M. X., Pinto, M., & Sousa, E. (2012). Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochemical Pharmacology, 83(1), 57–68. https://doi.org/10.1016/j.bcp.2011.10.004.PubMedCrossRef

187.

Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015). Cancer nanomedicine: from targeted delivery to combination therapy. Trends in Molecular Medicine, 21(4), 223–232. https://doi.org/10.1016/j.molmed.2015.01.001.PubMedPubMedCentralCrossRef

188.

Nastiuk, K. L., & Krolewski, J. J. (2016). Opportunities and challenges in combination gene cancer therapy. Advanced Drug Delivery Reviews, 98, 35–40. https://doi.org/10.1016/j.addr.2015.12.005.PubMedCrossRef

189.

Zheng, W., Yin, T., Chen, Q., Qin, X., Huang, X., Zhao, S., et al. (2016). Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III beta-tubulin in drug-resistant breast cancers. Acta Biomaterialia, 31, 197–210. https://doi.org/10.1016/j.actbio.2015.11.041.PubMedCrossRef

190.

Mitchell, M. J., Chen, C. S., Ponmudi, V., Hughes, A. D., & King, M. R. (2012). E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. Journal of Controlled Release, 160(3), 609–617. https://doi.org/10.1016/j.jconrel.2012.02.018.PubMedPubMedCentralCrossRef

191.

Pradhan, P., Giri, J., Rieken, F., Koch, C., Mykhaylyk, O., Doblinger, M., et al. (2010). Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. Journal of Controlled Release, 142(1), 108–121. https://doi.org/10.1016/j.jconrel.2009.10.002.PubMedCrossRef

192.

Li, Y., Wang, H., Wang, K., Hu, Q., Yao, Q., Shen, Y., et al. (2017). Targeted co-delivery of PTX and TR3 siRNA by PTP peptide modified dendrimer for the treatment of pancreatic cancer. Small, 13(2). https://doi.org/10.1002/smll.201602697.

193.

Khanna, A., Mahalingam, K., Chakrabarti, D., & Periyasamy, G. (2011). Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cellular & Molecular Biology Letters, 16(1), 101–113. https://doi.org/10.2478/s11658-010-0043-z.CrossRef

194.

Kars, M. D., Iseri, O. D., & Gunduz, U. (2010). Drug resistant breast cancer cells overexpress ETS1 gene. Biomedicine & Pharmacotherapy, 64(7), 458–462. https://doi.org/10.1016/j.biopha.2010.01.008.CrossRef

195.

Wu, M., Liu, X., Jin, W., Li, Y., Li, Y., Hu, Q., et al. (2017). Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy. Journal of Controlled Release, 253, 110–121. https://doi.org/10.1016/j.jconrel.2017.03.011.PubMedCrossRef

196.

Gottesman, M. M., & Pastan, I. H. (2015). The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. Journal of the National Cancer Institute, 107(9), djv222. https://doi.org/10.1093/jnci/djv222.

197.

Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute, 92(16), 1295–1302.PubMedCrossRef

198.

Jang, M., Han, H. D., & Ahn, H. J. (2016). A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy. Scientific Reports, 6, 32363. https://doi.org/10.1038/srep32363.PubMedPubMedCentralCrossRef

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

RNA interference-based therapy and its delivery systems

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

Correction to: Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

miR-155 in cancer drug resistance and as target for miRNA-based therapeutics

Biographies

Preface

MiR-181 family-specific behavior in different cancers: a meta-analysis view

Keynote webinar | Spotlight on antibody–drug conjugates in cancer